RxDoctor Payments DataLook up a doctor →

Vanessa Sandifer, MD

Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1104002898

Payments from drug & device makers

$14,355in general payments, 2019–2025

Across 803 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Abbott$1K
  • Dexcom, Inc.$972
  • Amgen$795
  • Novartis$687
  • plus $7K from 52 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk93$1,878
Lilly USA, LLC104$1,636
Abbott68$1,137
Dexcom, Inc.51$972
Amgen(2 entities)49$795
Novartis41$687
AstraZeneca(2 entities)42$640
Insulet Corporation27$620
Corcept Therapeutics30$552
Bayer27$504
Boehringer Ingelheim28$460
Sanofi-aventis U.S. LLC25$401
Merck22$394
Recordati_rare_diseases_inc.11$343
Esperion Therapeutics, Inc.17$315
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$247
Medtronic(2 entities)9$184
Amneal Pharmaceuticals LLC10$174
Tandem Diabetes Care, Inc.10$159
Lifescan, Inc.11$159
Xeris Pharmaceuticals, Inc.7$157
Pfizer10$150
AbbVie9$149
GRT US Holding, Inc.3$121
BD7$110
Ascendis Pharma Endocrinology Inc6$106
BETA Bionics, Inc.7$105
Valeritas, Inc.4$103
IBSA Pharma Inc.6$93
Kyowa Kirin, Inc.5$86
Sequel Med Tech, LLC4$78
Neurocrine Biosciences, Inc.4$77
Antares Pharma, Inc.3$76
Amryt Pharma Holdings Ltd3$76
Cequr Corporation2$74
Astellas Pharma US Inc3$53
Zealand Pharma US, Inc.3$40
Johnson & Johnson3$39
Embecta Corp.2$36
Acella Pharmaceuticals, LLC2$31
Takeda Pharmaceuticals U.S.A., Inc.2$29
Shire North American Group Inc2$28
Ascensia Diabetes Care US Inc.2$28
Nalpropion Pharmaceuticals LLC2$23
Eisai Inc.1$22
Radius Health, Inc.1$21
Alfasigma USA, Inc.1$20
Halozyme Inc1$19
Ultragenyx Pharmaceutical Inc.1$19
Amphastar Pharmaceuticals, Inc.1$18
Vifor Pharma, Inc.1$17
Aegerion Pharmaceuticals, Inc.1$17
Nestle Healthcare Nutrition Inc.1$16
Regeneron Healthcare Solutions, Inc.1$15
Amarin Pharma, Inc.1$14
Tolmar, Inc.1$13
Kowa Pharmaceuticals America, Inc.1$11
Senseonics, Incorporated1$11

How this compares

$14,355 in reported general payments places this provider in the 65th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.

See all endocrinology, diabetes & metabolism providers in Mississippi

Medicare billing

Part B allowed, 2024
$163,689
Medicare patients
413
Services billed
5,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →